Top Five CRO Signs Agreement with NewCardio
A top five CRO has signed a Master Services Agreement (MSA) with NewCardio, reports the Santa Clara, CA-based cardiac diagnostic and services company. The agreement gives the unspecified CRO a license to use NewCardio's QTinno software, which, according to the company's Web site, "provides fully automated and comprehensive analysis of QT intervals and other ECG markers for cardiac safety assessment in drug development."
"The adoption of QTinno by the clinical pharmacology units at this top five CRO will enable them to deliver quality TQT/QT studies with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," says Vincent Renz, NewCardio's President and Chief Operating Officer, in a company press release.
By adding this software to its existing offerings, the CRO will also be able to "capture additional" revenue because it will be able to provide customers with more services, the press release reports.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
